Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT02234960
A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- William R. Drobyski, MD
- Target Recruit Count
- 45
- Registration Number
- NCT02206035
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 82
- Registration Number
- NCT02165345
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇲🇽Hospital Infantil de México "Federico Gomez"; Rheumatology, Mexico, Mexico
🇲🇽Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria, Monterrey, Mexico
Tocilizumab for Renal Graft Inflammation
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Flavio Vincenti
- Target Recruit Count
- 33
- Registration Number
- NCT02108600
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 18
- Registration Number
- NCT02101333
- Locations
- 🇫🇷
Department of internal medicine, Saint-Antoine, Paris, France
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT02097524
Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Spanish Foundation of Rheumatology
- Target Recruit Count
- 122
- Registration Number
- NCT02087696
- Locations
- 🇪🇸
Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
🇪🇸Hospital Universitario Araba (Sede Txagorritxu), Vitoria-Gasteiz, Alava, Spain
🇪🇸Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT02057770
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
AIDS 347: IL-6 Blockade in Treated HIV Infection
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Case Western Reserve University
- Target Recruit Count
- 34
- Registration Number
- NCT02049437
- Locations
- 🇺🇸
Case Clinical Research Site, Cleveland, Ohio, United States
A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 133
- Registration Number
- NCT02046616
- Locations
- 🇩🇰
Aalborg Universitetshospital Nord, Reumatologisk Afdeling, Alborg, Denmark
🇩🇰Gentofte Hospital, Medicinsk Afd. C, Klinik for Gigt- og Rygsygdomme, Hellerup, Denmark
🇩🇰Glostrup Hospital, Reumatologisk Afdeling, Ambulatoriet, Glostrup, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.